Eshelman Ventures: Funding, Team & Investors | Startup Intros

Loading organizations...

Eshelman Ventures: Funding, Team & Investors | Startup Intros

Financial History

Total Raised

N/A

Valuation

N/A

Investments Made

Date	Company	Round	Lead Investor(s)	Co-Investor(s)
Aug 25, 2025	Incyclix Bio	$11.3M Series B Extension	—	Cape Fear BioCapital, Eli Lilly and Company, Fred Eshelman, Pharmacosmos
Apr 4, 2022	Incyclix Bio	$30.0M Series B	Sid Subramony	Fred Eshelman, Nathaniel Brooks Horwitz
Aug 5, 2020	Incyclix Bio	$6.0M Other Equity	Fred Eshelman	—
Dec 1, 2019	Kinnate Biopharma	$75.0M Series B	—	AMR Action Fund, Foresite Capital, General Atlantic, Hbm Partners, OrbiMed, SR One, The Column Group, Versant Ventures, Vivo Capital, Nextech Invest, Vida Ventures
May 1, 2016	G1 Therapeutics	$47.0M Series C	Bihua Chen	Catalio Capital, Hatteras Venture Partners, RA Capital, Ryan Allis, AJU IB Investment, Cowen Private Investments, Franklin Templeton, Lumira Ventures, MedImmune Ventures, Mountain Group Partners, RA Capital Management, Rock Springs Capital, Tavistock Group
Apr 14, 2015	Innocrin Pharmaceuticals	$28.0M Series D	Fred Eshelman	A&B Equity Holdings, Hatteras Venture Partners, Intersouth Partners, Lilly Ventures, Novartis
Feb 1, 2015	G1 Therapeutics	$33.0M Series B	Fred Eshelman, Peter Kolchinsky	Catalio Capital, Hatteras Venture Partners, RA Capital, Ryan Allis, Boxer Capital, Lumira Ventures, MedImmune Ventures, Mountain Group Partners